Sigma-Aldrich taken over by Merck for, page-9

Truly, I understand everyone's desire to see this happen quickly, but safety and adherence is more important. To temper some of your points...
(1). No second patient has been dosed in the HCV study.
Regardless of the delay, the last PR said it would be AT LEAST 28 days, not only 28 days.
(2). No additional sites have opened as French promised.
according to clinical trials dot gov, both sites are now open for recruiting.
(3). I have not been following these trials as much, so I can't honestly respond to those ATM.

All that aside, there has been NO negative news. Nobody has died or been seriously injured in all the areas that ddRNAi has been used up to this point. Calimmune is still advancing their HIV program, and second dosing should be soon. There is nothing that I can see to worry about except for a temporary dip in share price while we wait. All long Benitec holders know this trial needs to be followed precisely, since benitec is breaking new ground and don't want to screw it up. It's just a waiting game right now. The share price will reflect their true worth when robust data on efficacy comes through. For now, we want to do no harm.